Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q3 2017 · 10-Q
Revenue$3.10M$3.10M+73.7% vs Q3 2016 Net Income-$622.79K-$622.79KN/M vs Q3 2016 EPS Diluted-$0.06-$0.06N/M vs Q3 2016 Gross Profit$1,398,931+31.6% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flowderived-$788,945N/M Free Cash Flowderived-$793,656N/M Margins · derivedGross margin45.1%−14.4 pt vs Q3 2016
Operating margin-20.3%−6.3 pt vs Q3 2016
Net margin-20.1%−6.5 pt vs Q3 2016
ended Sep 30, 2017 · filed Nov 2, 2017 · 33 d after period end